Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of …
F Guilhot, M Gardembas, P Rousselot, M Tulliez… - Seminars in …, 2003 - Elsevier
Imatinib (Gleevec)(formerly STI571) has been shown to selectively inhibit the tyrosine kinase
domain of the oncogenic BCR-ABL fusion protein of chronic myelogenous leukemia (CML) …
domain of the oncogenic BCR-ABL fusion protein of chronic myelogenous leukemia (CML) …
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous …
M Gardembas, P Rousselot, M Tulliez, M Vigier… - Blood, 2003 - ashpublications.org
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively
inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent …
inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent …
[PDF][PDF] Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year …
I Iacobucci, G Rosti, M Amabile, A Poerio… - Journal of clinical …, 2006 - researchgate.net
Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid
Leukemia Who Obtained a Complete Cytogeneti Page 1 Comparison Between Patients With …
Leukemia Who Obtained a Complete Cytogeneti Page 1 Comparison Between Patients With …
Imatinib compared with imatinib/cytarabine for the first-line treatment of early Philadelphia chromosome–positive chronic myeloid leukemia: results of a randomized …
R Hurtado-Monroy, P Vargas-Viveros, M Candelaria… - Clinical Leukemia, 2008 - Elsevier
Background In an attempt to improve the cytogenetic and molecular response rate in
Philadelphia chromosome–positive early chronic-phase CML, we compared the …
Philadelphia chromosome–positive early chronic-phase CML, we compared the …
Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome
P Le Coutre, KA Kreuzer, IK Na… - American journal of …, 2003 - Wiley Online Library
Previous clinical trials with the tyrosine kinase inhibitor imatinib in chronic‐phase
Philadelphia chromosome‐positive chronic myelogenous leukemia (CML) resulted in 95 …
Philadelphia chromosome‐positive chronic myelogenous leukemia (CML) resulted in 95 …
[HTML][HTML] High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic …
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated
Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results …
Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results …
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous …
P La Rosee, ME O'Dwyer, BJ Druker - Leukemia, 2002 - nature.com
Clinical phase I/II studies with the Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec,
formerly STI571) for the treatment for chronic myelogenous leukemia (CML) demonstrated …
formerly STI571) for the treatment for chronic myelogenous leukemia (CML) demonstrated …
Imatinib: a review of its use in chronic myeloid leukaemia
MD Moen, K McKeage, GL Plosker, MAA Siddiqui - Drugs, 2007 - Springer
Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final …
M Baccarani, BJ Druker, S Branford, DW Kim… - International journal of …, 2014 - Springer
The TOPS trial evaluated high-(800 mg/day; n= 319) versus standard-dose (400 mg/day; n=
157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic …
157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic …
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase …
HM Kantarjian, S O'Brien, J Cortes, FJ Giles, MB Rios… - Cancer, 2003 - Wiley Online Library
Abstract BACKGROUND The I nternational R andomized study of I nterferon‐alpha plus
cytarabine (IFN‐α plus ara‐C) versus S TI571 (imatinib mesylate)[IRIS trial] in patients with …
cytarabine (IFN‐α plus ara‐C) versus S TI571 (imatinib mesylate)[IRIS trial] in patients with …
相关搜索
- cytarabine for the treatment myelogenous leukemia
- imatinib in combination myelogenous leukemia
- cytarabine for the treatment chronic phase
- imatinib in combination design of phase
- design of phase myelogenous leukemia
- cytarabine for the treatment imatinib mesylate
- survival in patients chronic phase
- cml patients philadelphia chromosome
- imatinib mesylate chronic phase
- philadelphia chromosome chronic phase
- cml patients response rates
- leukemia cells drug combinations
- philadelphia chromosome leukemia group
- cml patients clinical outcome
- combination with cytarabine myelogenous leukemia
- combination with cytarabine design of phase